Company profile
AGENUS INC
NASDAQ:AGENBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (4)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| BALSTILIMAB | phase2 | — | 3 | completed, terminated, withdrawn |
| QUILLAJA SAPONIN (QS-21) | phase2 | — | 5 | completed, terminated |
| VITESPEN | phase3 | — | 3 | completed, terminated |
| ZALIFRELIMAB | phase2 | — | 3 | completed, terminated, withdrawn |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (29)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05033132 | phase2 | withdrawn | 2021-10-01 | 2024-12-30 | Agenus Inc. | A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer |
| NCT00081809 | phase2 | completed | 2000-03-01 | 2005-06-01 | Agenus Inc. | A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma |
| NCT05025085 | phase1 | completed | 2021-10-04 | 2023-07-11 | Agenus Inc. | A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors |
| NCT04156100 | phase1 | terminated | 2019-12-10 | 2021-04-08 | Agenus Inc. | A Study in Subjects With Advanced Solid Tumors |
| NCT03104699 | phase1_2 | completed | 2017-04-11 | 2022-06-15 | Agenus Inc. | A Study of AGEN2034 in Advanced Tumors and Cervical Cancer |
FDA applications (0)
No records yet.